Clearwater Capital Advisors LLC lowered its position in ARK Genomic Revolution ETF (BATS:ARKG – Free Report) by 65.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 15,631 shares of the company’s stock after selling 29,666 shares during the quarter. Clearwater Capital Advisors LLC’s holdings in ARK Genomic Revolution ETF were worth $848,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. BCV Asset Management Inc. purchased a new position in ARK Genomic Revolution ETF in the 3rd quarter valued at approximately $201,000. Allworth Financial LP raised its holdings in ARK Genomic Revolution ETF by 15.6% during the 3rd quarter. Allworth Financial LP now owns 3,336 shares of the company’s stock valued at $181,000 after acquiring an additional 450 shares during the period. Lido Advisors LLC purchased a new stake in shares of ARK Genomic Revolution ETF during the third quarter worth $261,000. Clientfirst Wealth Management LLC lifted its position in shares of ARK Genomic Revolution ETF by 2.0% during the third quarter. Clientfirst Wealth Management LLC now owns 24,127 shares of the company’s stock worth $1,308,000 after acquiring an additional 475 shares in the last quarter. Finally, StoneX Group Inc. purchased a new stake in shares of ARK Genomic Revolution ETF during the third quarter worth $406,000.
ARK Genomic Revolution ETF Price Performance
ARK Genomic Revolution ETF stock opened at $43.20 on Monday. The firm has a market capitalization of $1.87 billion, a P/E ratio of 20.11 and a beta of 1.73. ARK Genomic Revolution ETF has a one year low of $24.60 and a one year high of $58.83. The business has a fifty day moving average price of $49.58 and a 200-day moving average price of $38.08.
About ARK Genomic Revolution ETF
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
See Also
- Five stocks we like better than ARK Genomic Revolution ETF
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
